- Translational Biomedical Research can be defined as ‘bench to bedside’ or patient-focused biomedical research, the aim of which is to translate existing knowledge about cancer biology into techniques and tools that will accelerate progress towards patient treatment. Research in this area will build upon basic biological discoveries and improves their Translational Biomedical potential through pre-clinical studies. Much of the outputs of Translational Biomedical research naturally merge into Clinical research, the next area of focus. Please note, applications in drug design, SAR (structure–activity relationship) analysis, drug screening or basic biomedical research will not be considered at this time.
- Clinical Research involves organised investigations in people to examine the benefits of new approaches to treatment and care. For example, looking to see if a new medicine can improve survival for a particular form of cancer. As well as funding these drug-based trials (so called IMP trials), the Irish Cancer Society is also interested in funding non-drug-based trials (non-IMP trials) in areas such as diagnostics, technology, radiotherapy, surgery, psycho-oncology, exercise, nutrition, and combinations of these.
Please Note: The funding amount for the ‘Translational Biomedical and Clinical’ stream is €185,000 (& additional €5,000 Mobility Element). The €185,000 is inclusive of €50,000 ring-fenced for lab consumables. Total award €190,000.
